Applied Therapeutics (APLT) AI Stock Analysis

• Market Cap: $14.52M
• Dividend Yield: N/A
• Average Volume (3M): 17.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.91
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 35
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 144,300,670
• 10 Day Avg. Volume: 47,414,159
• 30 Day Avg. Volume: 17,542,089
• PEG Ratio: 0.02
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 262.57
• P/FCF Ratio: -1.42
• Enterprise Value/Market Cap: 5.41
• Enterprise Value/Revenue: 78.60
• Enterprise Value/Gross Profit: -2.76
• Enterprise Value/Ebitda: -0.78
• 1Y Price Target: $0.25
• Price Target Upside: 150.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.10 ▲(1.00% Upside)

The score is primarily weighed down by weak financial performance—large operating losses, persistent heavy cash burn, and negative equity—alongside strongly bearish technical signals (price below key moving averages and negative MACD). Valuation offers limited offset given ongoing losses (negative P/E) and no dividend yield data.

Positive Factors

Revenue Generation

The initial revenue generation indicates progress in commercializing drug candidates, which is crucial for transitioning from a clinical-stage to a revenue-generating company.

Scientific Expertise

The company's focus on high unmet medical needs and novel drug candidates positions it well to potentially capture significant market share in niche therapeutic areas.

Partnership Potential

Strategic partnerships can provide milestone payments and royalties, enhancing cash flow and reducing financial risk, which is vital for growth and sustainability.

Negative Factors

Profitability Challenges

Ongoing net losses and negative profit margins indicate significant challenges in achieving profitability, which can hinder long-term financial stability.

Cash Flow Dependence

Reliance on external funding for operations poses a risk, especially if the funding environment tightens, impacting the company's ability to sustain operations.

Financial Instability

Negative stockholders' equity reflects financial instability, which can limit the company's ability to invest in growth and innovation, affecting long-term prospects.

Applied Therapeutics Business Overview & Revenue Model

Company Description

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

How the Company Makes Money

Applied Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company invests heavily in clinical trials to bring its products to market, seeking regulatory approvals from agencies like the FDA. Once approved, revenues are expected from product sales and potential partnerships or licensing agreements with larger pharmaceutical companies. These partnerships may provide milestone payments, royalties, or co-development funding. The success of its revenue model is contingent on the successful clinical development and commercialization of its therapies.

Applied Therapeutics Financial Statement Overview

Summary

Applied Therapeutics is beginning to generate revenue, but profitability and cash flow remain significant challenges. The company is reliant on external financing to sustain its operations, which could pose risks if the funding environment tightens. Despite some improvements in financial position, the biotechnology company needs to focus on achieving operational efficiencies and managing expenses to move towards profitability.

Income Statement

Applied Therapeutics has shown a significant increase in total revenue from $0 to $9.993 million in 2023 and to $455,000 in 2024, indicating initial revenue generation in the last two years. However, the company is still reporting substantial net losses, with a negative net profit margin indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are deeply negative, reflecting high operating expenses relative to revenue.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio due to low total debt, but stockholders' equity has been negative in previous periods, indicating financial instability. The equity ratio is relatively low, reflecting a higher proportion of liabilities to assets. While there is an improvement in total assets and stockholders' equity in 2024, the company remains highly leveraged.

Cash Flow

Operating cash flow remains negative, but there is a significant increase in financing cash flow, which suggests reliance on external funding to support operations. Free cash flow remains negative, indicating that the company is not yet generating cash from its operations, which is a concern for long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.00M	455.00K	9.99M	0.00	0.00	0.00
Gross Profit	-28.45M	-48.29M	-43.91M	-441.00K	0.00	0.00
EBITDA	-100.52M	-104.30M	-64.53M	-82.07M	-105.62M	-94.47M
Net Income	-18.14M	-105.62M	-119.76M	-82.51M	-105.58M	-93.96M
Balance Sheet
Total Assets	34.37M	86.69M	54.83M	38.36M	89.89M	104.51M
Cash, Cash Equivalents and Short-Term Investments	11.95M	79.40M	49.90M	30.58M	80.82M	96.83M
Total Debt	2.50M	2.79M	777.00K	1.98M	2.12M	2.81M
Total Liabilities	34.94M	29.68M	71.98M	34.30M	27.35M	22.57M
Stockholders Equity	-561.00K	57.01M	-17.15M	4.06M	62.54M	81.94M
Cash Flow
Free Cash Flow	-86.85M	-84.31M	-55.17M	-78.09M	-90.73M	-78.21M
Operating Cash Flow	-86.85M	-84.31M	-55.17M	-78.09M	-90.73M	-78.21M
Investing Cash Flow	0.00	0.00	13.87M	13.17M	12.43M	-19.47M
Financing Cash Flow	-75.00K	113.81M	74.54M	27.69M	74.72M	136.29M

Applied Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLT, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.33, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 25.93 is Positive, neither overbought nor oversold. The STOCH value of 34.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APLT.

Applied Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STTK	53 Neutral	$300.58M	-4.50	-57.84%	―	-84.46%	33.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRDF	48 Neutral	$207.47M	-3.62	-102.71%	―	-27.29%	16.40%
NKTX	48 Neutral	$148.45M	-1.57	-26.69%	―	―	25.84%
FATE	47 Neutral	$121.12M	-0.81	-52.35%	―	-46.92%	20.26%
APLT	43 Neutral	$14.52M	-0.99	-680.47%	―	―	―
ONCY	43 Neutral	$104.13M	-3.53	-745.66%	―	―	―

Applied Therapeutics Corporate Events

Applied Therapeutics Announces Merger with Cycle Group

On December 11, 2025, Applied Therapeutics announced a merger agreement with Cycle Group Holdings Limited, where Cycle will acquire all outstanding shares of Applied Therapeutics. The transaction involves a tender offer for $0.088 per share in cash plus a contingent value right (CVR) for potential additional payments based on certain milestones. The merger is expected to close in the first quarter of 2026, subject to customary conditions. The Applied Board of Directors unanimously approved the agreement, viewing it as the best strategic option for the company and its shareholders.

The most recent analyst rating on (APLT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.

Applied Therapeutics Announces Strategic Review and Workforce Cuts

On November 20, 2025, Applied Therapeutics announced a strategic review to explore alternatives like mergers or partnerships to maximize shareholder value. As part of this process, the company plans to reduce its workforce by 46% by the end of December 2025, aiming to conserve cash and maintain its commitment to developing treatments for rare diseases.

The most recent analyst rating on (APLT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.